Your browser is no longer supported. Please, upgrade your browser.
Mereo BioPharma Group plc
Index- P/E- EPS (ttm)-7.55 Insider Own0.24% Shs Outstand110.95M Perf Week-7.77%
Market Cap210.80M Forward P/E- EPS next Y-11.50 Insider Trans0.00% Shs Float58.77M Perf Month-11.21%
Income-220.70M PEG- EPS next Q-4.00 Inst Own82.70% Short Float14.24% Perf Quarter-31.65%
Sales- P/S- EPS this Y- Inst Trans-2.35% Short Ratio10.47 Perf Half Y-41.90%
Book/sh1.38 P/B1.38 EPS next Y- ROA- Target Price9.33 Perf Year-19.83%
Cash/sh0.69 P/C2.75 EPS next 5Y- ROE- 52W Range1.73 - 4.71 Perf YTD-46.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.67% Beta-
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low9.83% ATR0.14
Employees50 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)35.68 Volatility9.69% 6.70%
OptionableYes Debt/Eq1.64 EPS Q/Q- Profit Margin- Rel Volume0.93 Prev Close2.06
ShortableYes LT Debt/Eq1.06 Earnings- Payout- Avg Volume799.50K Price1.90
Recom1.30 SMA20-14.70% SMA50-16.75% SMA200-36.56% Volume741,285 Change-7.77%
May-05-21Initiated BTIG Research Buy $10
Apr-05-21Initiated Needham Buy $10
Nov-09-21 08:00AM  
Nov-04-21 09:00AM  
Oct-31-21 10:30AM  
Oct-26-21 10:26AM  
Oct-13-21 08:00AM  
Oct-01-21 04:31PM  
Sep-20-21 08:00AM  
Sep-09-21 08:00AM  
Aug-02-21 08:00AM  
Jul-19-21 07:04PM  
Jun-02-21 09:45AM  
May-27-21 08:00AM  
May-04-21 08:00AM  
Apr-30-21 08:00AM  
Apr-08-21 08:30AM  
Mar-31-21 05:02PM  
Feb-25-21 11:33AM  
Feb-18-21 07:00AM  
Feb-12-21 12:41PM  
Feb-10-21 07:00AM  
Feb-09-21 04:03PM  
Dec-21-20 10:26AM  
Dec-18-20 11:15AM  
Dec-17-20 04:05PM  
Dec-15-20 01:00PM  
Dec-07-20 10:59PM  
Nov-23-20 07:05AM  
Nov-16-20 07:00AM  
Nov-10-20 07:23AM  
Oct-20-20 07:00AM  
Oct-19-20 07:00AM  
Sep-29-20 07:00AM  
Sep-24-20 07:00AM  
Sep-16-20 08:00AM  
Sep-04-20 05:08AM  
Aug-25-20 07:00AM  
Aug-17-20 03:30PM  
Jun-30-20 07:00AM  
Jun-16-20 07:00AM  
Jun-04-20 07:00AM  
Mar-27-20 08:00AM  
Feb-28-20 07:00AM  
Feb-19-20 07:21AM  
Feb-12-20 08:00AM  
Feb-11-20 07:23AM  
Feb-10-20 07:00AM  
Jan-14-20 07:00AM  
Jan-13-20 07:00AM  
Nov-11-19 06:30AM  
Oct-09-19 08:18AM  
Oct-07-19 08:00AM  
Sep-17-19 07:00AM  
Sep-10-19 08:00AM  
Sep-04-19 08:00AM  
Jul-16-19 08:00AM  
Jul-15-19 08:00AM  
Jun-14-19 08:47AM  
Jun-13-19 08:00AM  
May-30-19 07:33AM  
May-03-19 12:09PM  
Apr-29-19 02:00AM  
Apr-26-19 08:00AM  
Apr-24-19 09:30AM  
Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.